EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Drug–Carrier Interactions in PEGylated Liposomal Doxorubicin‐Associated Renal Toxicity: A Systems‐Level Analysis of Complement–Coagulation Crosstalk

Huirong Ye, Youfa Qin iD, Liping Chen, Suidong Ouyang iD, Huicheng Ye, Weidong Liu iD

Journal of Cellular and Molecular Medicine · 2026-11 · 30 (22)

DOI: 10.1111/jcmm.71464 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 18.11.2026. Verfasst von Huirong Ye und 5 weiteren Autor:innen. Beteiligte Einrichtung: Breast Disease Diagnosis and Treatment Center, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, Chi…. Hauptthemen laut MEDLINE: Doxorubicin, Complement System Proteins, Blood Coagulation, Kidney. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangdong Basic and Applied Basic Research Foundation, Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PEGylated liposomal doxorubicin (PLD) is widely used in cancer therapy, yet rare cases of renal‐limited thrombotic microangiopathy (TMA) have been reported, characterized by glomerular endothelial injury and microvascular thrombosis. The mechanisms underlying this distinct nephrotoxicity remain poorly understood, particularly the potential contribution of drug–carrier interactions. Here, we developed an integrated multi‐layer network toxicology framework to systematically investigate PLD‐associated renal injury. By integrating doxorubicin‐associated targets, carrier‐associated complement pathways, nephrotoxicity‐associated genes and renal injury‐responsive transcriptomic signatures, we identified 98 computationally derived candidate genes and constructed a mechanistic interaction network. Enrichment analyses highlighted complement activation and complement–coagulation crosstalk, while transcriptomic data indicated endothelial dysfunction, inflammatory activation and oxidative stress. PTGS2 and SERPINE1 were prioritized as candidate molecular convergence nodes linking inflammatory and prothrombotic signalling, and molecular docking and dynamics analyses supported in silico interactions between doxorubicin and these proteins. Immune‐related transcriptional signature analyses further indicated enrichment of gene programs associated with macrophage, neutrophil and dendritic‐cell signatures in renal injury. These findings suggest a candidate dual‐hit model in which doxorubicin‐induced intracellular stress and carrier‐associated complement activation may converge toward endothelial injury as well as inflammation–coagulation crosstalk, potentially contributing to PLD‐associated renal TMA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinComplement System ProteinsBlood CoagulationKidneyDrug CarriersPolyethylene GlycolsHumansComplement ActivationAnimalsTranscriptomeMolecular Docking SimulationOxidative Stress

Stichwörter der Autor:innen

PEGylated liposomal doxorubicinacute kidney injurynephrotoxicitysystems pharmacologythrombotic microangiopathy

Substanzen

DoxorubicinPolyethylene Glycolsliposomal doxorubicinComplement System ProteinsDrug Carriers

Autor:innen und Institutionen

  • Breast Disease Diagnosis and Treatment Center, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, China.
  • Dongguan Key Laboratory of Precision Medicine Individualized Treatment Development, Department of Clinical Pharmacy, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, China.
  • Dongguan Innovation Institute, Guangdong Medical University, Dongguan, China.
  • Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China.
  • Dongguan Key Laboratory of Immune Regulation and Prevention of Pulmonary Diseases, Liaobu Hospital of Dongguan City, Dongguan, China.
  • Department of General Practice, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, China.

ORCID-Profile: Youfa Qin, Suidong Ouyang, Weidong Liu

Förderung

  • Guangdong Basic and Applied Basic Research Foundation
  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Ye, H., Qin, Y., Chen, L., Ouyang, S., Ye, H., & Liu, W. (2026). Drug–Carrier Interactions in PEGylated Liposomal Doxorubicin‐Associated Renal Toxicity: A Systems‐Level Analysis of Complement–Coagulation Crosstalk. Journal of Cellular and Molecular Medicine, 30(22). https://doi.org/10.1111/jcmm.71464

Vancouver

Ye H, Qin Y, Chen L, Ouyang S, Ye H, Liu W. Drug–Carrier Interactions in PEGylated Liposomal Doxorubicin‐Associated Renal Toxicity: A Systems‐Level Analysis of Complement–Coagulation Crosstalk. Journal of Cellular and Molecular Medicine. 2026;30(22). doi:10.1111/jcmm.71464

BibTeX
@article{Ye2026,
  author = {Ye, Huirong and Qin, Youfa and Chen, Liping and Ouyang, Suidong and Ye, Huicheng and Liu, Weidong},
  title = {Drug–Carrier Interactions in PEGylated Liposomal Doxorubicin‐Associated Renal Toxicity: A Systems‐Level Analysis of Complement–Coagulation Crosstalk},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2026},
  volume = {30},
  number = {22},
  doi = {10.1111/jcmm.71464}
}
Kostenlos starten →